What are the brand names (Neupogen – filgrastim, Neulasta – pegfilgrastim) for granulocyte colony‑stimulating factor (G‑CSF), how is it used to optimize neutropenia, and which specialties—including dermatology—commonly use it?

Brand Names and Use of G-CSF for Neutropenia Management

The primary brand names for granulocyte colony-stimulating factor (G-CSF) are Neupogen® (filgrastim) and Neulasta® (pegfilgrastim), and yes, as a dermatologist you can use these agents when prescribing myelosuppressive chemotherapy or other medications that cause significant neutropenia. 12

Available G-CSF Formulations

The G-CSF products available include:

• Filgrastim (Neupogen®): Short-acting G-CSF requiring daily injections
• Pegfilgrastim (Neulasta®): Long-acting pegylated G-CSF requiring only once-per-cycle dosing
• Tbo-filgrastim: Another short-acting formulation
• Filgrastim-sndz: Biosimilar to filgrastim

324

How to Use G-CSF to Optimize Neutropenia

Timing of Administration

For pegfilgrastim (Neulasta®):

• Administer 6 mg subcutaneously once, 1-3 days after chemotherapy (ideally at least 24 hours post-chemotherapy)
• Never give on the same day as chemotherapy - while technically possible in exceptional circumstances, same-day administration is significantly less effective than next-day dosing 35
• Continue prophylaxis through all cycles of chemotherapy, not just the first 1-2 cycles 3

For filgrastim (Neupogen®):

• Start 1-3 days after myelotoxic chemotherapy
• Dose: 5 mcg/kg/day subcutaneously
• Continue until absolute neutrophil count (ANC) reaches 2-3 × 10⁹/L
• Requires daily injections throughout the at-risk period 33

Administration Technique

• Route: Subcutaneous injection (preferred) 31
• Sites: Thigh, abdomen (avoiding 2 inches around navel), upper outer buttocks, or outer upper arm 11
• Storage: Refrigerate at 2-8°C; allow to reach room temperature 30 minutes before injection 1
• Important: Do not shake the medication 1

Specialty-Specific Considerations for Dermatologists

You can absolutely use G-CSF in dermatology practice, particularly when:

• Prescribing methotrexate at high doses for severe psoriasis or other inflammatory conditions
• Using cyclophosphamide for severe autoimmune blistering diseases or vasculitis
• Managing patients on azathioprine or mycophenolate who develop neutropenia
• Treating cutaneous T-cell lymphoma with chemotherapy regimens

When to Consider G-CSF Prophylaxis

The ASCO guidelines recommend primary prophylaxis when:

• High-risk regimens (>20% risk of febrile neutropenia)
• Intermediate-risk regimens (10-20% risk) PLUS patient risk factors including:
  • Age ≥65 years
  • Previous episodes of febrile neutropenia
  • Poor performance status
  • Advanced disease
  • No antibiotic prophylaxis planned

36

Practical Algorithm for Dermatology Use

1. Assess neutropenia risk of your planned treatment regimen
2. If high-risk or intermediate-risk with patient factors: Prescribe pegfilgrastim 6 mg for once-per-cycle convenience
3. Schedule administration: 24-48 hours after chemotherapy/immunosuppressant dose
4. Monitor ANC before each treatment cycle
5. Continue prophylaxis through all planned cycles, not just initial cycles

Critical Safety Considerations

Monitor for these complications:

• Myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Watch for persistent cytopenias, easy bruising, bleeding, fever, or fatigue 1
• Splenic rupture: Rare but serious - counsel patients to report left upper quadrant or shoulder pain
• Acute respiratory distress syndrome: Monitor for respiratory symptoms
• Cutaneous vasculitis: Particularly relevant for dermatologists - purple spots or skin redness may indicate this complication 1
• Aortitis: Fever, abdominal pain, fatigue, back pain 1

Common Pitfalls to Avoid

• Don't administer pegfilgrastim on the same day as chemotherapy - this significantly reduces efficacy 5
• Don't stop prophylaxis after 1-2 cycles - maintain through all cycles to prevent late neutropenic complications 3
• Don't use pegfilgrastim in patients <45 kg - use weight-based filgrastim instead 3
• Don't forget the latex warning - the needle cap contains natural rubber latex 1
• Don't underdose short-acting G-CSF - patients often receive insufficient duration (mean 5 days when longer may be needed) 6

Efficacy Comparison

Pegfilgrastim offers comparable or superior efficacy to daily filgrastim with the major advantage of once-per-cycle dosing, which improves compliance and quality of life 324. The choice between agents depends on convenience, cost, and clinical situation, but all are effective for preventing febrile neutropenia 3.